Immunotherapy beyond cancer

As sponsors and biopharma developers expand immunotherapies into chronic indications, they face a critical execution gap: oncology development models fail in non-oncology settings. Lower risk tolerance, lower target-cell counts, and high competition require a fundamental shift in trial design, dosing, and patient engagement.

This whitepaper explores practical strategies for transitioning immunotherapies into chronic disease programs, spanning advanced modalities, trial architecture, and regulatory navigation.

Read to learn:

• Key applications for CAR-T, T-cell engagers, and ICIs in autoimmune, cardiometabolic, and reproductive health indications
• Methods for determining Optimal Biological Dose (OBD) to balance efficacy with lower patient risk tolerance
• Operational frameworks, such as hub-and-spoke trial models, to reduce patient burden and boost referral rates
• Innovative approaches to long-term follow-up, including clinical trial tokenisation
• Regulatory and market entry strategies to accelerate study timelines in crowded therapeutic areas

ICON applies appropriate transparency measures to identify AI-generated or AI-altered content. 
Videos on this site may have been modified using AI to provide audio and text captioning translations.
From the video player controls at the bottom:

• Select the headphone icon to choose a different language for audio narration.
• Select the closed captioning icon ('CC') to switch captions on or off, and to select your preferred language.